Santiago de Compostela, Spain – September 2026 – Oncostellae, a clinical-stage biopharmaceutical company focused on developing innovative therapies for immune-mediated diseases, today announced that it will attend BIO-Europe 2026, held in Cologne, Germany, from November 9–11, 2026.
BIO-Europe is one of Europe’s leading biopharma partnering events, bringing together thousands of biotechnology and pharmaceutical executives, investors and other life sciences professionals from around the world. The 2026 event will feature extensive one-to-one partnering opportunities and strategic discussions across the biopharmaceutical industry.
During the event, the Oncostellae team will hold one-to-one meetings with pharmaceutical companies, biotechnology companies, and investors to discuss the company’s development programs and potential collaboration opportunities. Particular emphasis will be placed on OST-122, Oncostellae’s lead program in inflammatory bowel disease (IBD), as the company prepares for its next stage of clinical development.
“BIO-Europe is an important opportunity to broaden our discussions with potential partners and investors as we approach the next value-creating milestones for OST-122,” said Guido Kurz, PhD, CEO of Oncostellae. “We are seeing growing interest in differentiated approaches to IBD, and we look forward to discussing how OST-122 could address important limitations associated with currently available therapies.”
Oncostellae is currently advancing preparations for a Phase 2b clinical study of OST-122 in ulcerative colitis, following encouraging clinical proof-of-concept data. The company is seeking strategic partnerships and financing opportunities to support the continued development of OST-122.
About Oncostellae
Oncostellae is a clinical-stage biopharmaceutical company developing innovative small-molecule therapies for diseases with significant unmet medical needs. The company’s lead program, OST-122, is a gut-restricted JAK inhibitor designed to deliver therapeutic activity in the gastrointestinal tract while minimizing systemic exposure and the safety liabilities associated with systemic JAK inhibition.
